|
65679784212eaade2e0ee2fc
|
2020
|
Germany
|
Bundesministerium für Wirtsch...aftliche Zusammenarbeit und Entwicklung
more
|
2020007115
|
201806009-3323
|
3
|
Uganda
|
South of Sahara
|
LDCs
|
ODA Grants
|
3
|
10
|
110
|
B01
|
0
|
0.203879
|
0
|
0
|
0
|
0.203879
|
|
0
|
|
0
|
Other health problems
|
Other health problems Other
|
100
|
IMPROVING REHABILITATIVE HEALT...H CARE SERVICES BY STRENGTHENING THE UNDERSERVED SECTOR PHYSIOTHERAPY IN UGANDA
more
|
Improving rehabilitative healt...h care services by strengthening the underserved sector physiotherapy in Uganda
more
|
Improving rehabilitative healt...h care services by strengthening the underserved sector physiotherapy in Uganda
more
|
|
12181
|
Medical education/training
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think-tank
more
|
|
|
|
65679784212eaade2e0ee2fd
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007621
|
GCRF-RSRFFLAIR-FR12020-FLR\R1\...201782
more
|
3
|
South Africa
|
South of Sahara
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.155188
|
0
|
0
|
0
|
0.155188
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ISOLATION AND RATIONAL REDESIG...N OF MONOCLONAL ANTIBODIES FOR USE AS PAN-REACTIVE NEXT-GENERATION SNAKE ANTIVENOMS FOR AFRICA
more
|
Isolation and rational redesig...n of monoclonal antibodies for use as pan-reactive next-generation snake antivenoms for Africa
more
|
Fellowship award based in Sout...h Africa. Developing safe, effective, next generation antivenom to treat snakebite, which kills or disfigures thousands in Africa every year and was recently recognized as a neglected tropical disease by the WHO. SDG 3.
more
|
NTD - Snakebites
|
12382
|
Research for prevention and co...ntrol of NCDs
more
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679784212eaade2e0ee2fe
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007635
|
GCRF-CICA-ICAR12020-ICAR120129...9
more
|
3
|
South Asia, regional
|
South & Central Asia
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.096191
|
0
|
0
|
0
|
0.096191
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ROLE OF HELICOBACTER IN PERSIS...TENT IMMUNE ACTIVATION & DEVELOPMENT OF CHOLANGIOCARCINOMA FOLLOWING INFECTION WITH LIVER FLUKE, OPISTHORCHIS VIVERRINI
more
|
Role of Helicobacter in persis...tent immune activation & development of cholangiocarcinoma following infection with liver fluke, Opisthorchis viverrini
more
|
Research Grant - Collaboration... between UK and Thailand. Investigating the factors that lead to liver disease and liver cancer in patients infected with liver-fluke, a common infection amongst impoverished people in South-East Asia which results in major socio-economic and healthcare problems within these poor communities. SDGs 3,17.
more
|
|
12382
|
Research for prevention and co...ntrol of NCDs
more
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679785212eaade2e0ee2ff
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006801
|
GCRF_EPSRC_AA_EP/R01437X/1
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.244814
|
0
|
0
|
0
|
0.244814
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
NOVEL LOW COST DIAGNOSTIC TOOL...S AND THEIR IMPACT IN AFRICA
more
|
Novel low cost diagnostic tool...s and their impact in Africa
more
|
Point of care testing is funda...mental in delivering health and economic sustainability in the Global South. Our project will enable low cost, effective and accurate diagnosis of, in the first instance, two infectious diseases, namely malaria and schistosomiasis. This will be achieved using a novel very low cost paper diagnostic method that is able to quantify the infectious agent's DNA in a patient sample in a multiplexed assay. The platform will allow the measurement of several diseases at the same time, thereby increasing the efficiency of healthcare provision in often hard to reach settings, as well as establishing the species of the infectious agent (e.g. malaria), which will provide actionable information to healthcare professionals, where drugs have different levels of activity for different species, thus helping in reducing the potential emergence/increase of drug resistance. We have already demonstrated the potential for these low cost assays as being both sensitive and specific and we now wish to develop new engineering approaches to improve their performance (in terms of their speed and ease of use) and evidence their impact so that they can find widespread application in both rural and urban environments in Uganda and Sierra Leone, and other endemic countries. As the assays are sensitive and quantitative, they have the potential to be used not only in the treatment of individuals, but also in eradication programmes, such as those advocated by the London 2020 accord, enabling the surveillance of disease re/emergence. To help communicate the value of repeated treatments, we plan to develop new engagement tools based upon a novel mobile phone imaging platform that enables patients to visualise the infectious agent in a sample, and to see the outcome of interventions (whether these be through drug administration or physical/cultural changes such as access to improved sanitation or bed nets). We also propose to measure the impact of our novel diagnostic and imaging platforms by collection of suitable, realistic, logistically feasible metrics, and the potential impacts (including resources, health outcomes, employment, income) of the interventions. We will also feed these into newly developed and parameterised economic models to predict the long-term benefits specific interventions may have. Finally, integral to the proposed research is an ambitious programme of impact, which includes public engagement over infectious disease diagnosis and STEM and capacity strengthening. We will also explore routes to delivery of the technologies both in the UK, where the provision of low-cost point-of-care diagnostics is of significant interest (through our industrial partners), and in LMICs. Our ambition is to explore whether, through not-for-profit business planning, we can develop the correct interactions with Governments, Hospitals and Charities/NGOs, to test whether we are able to scale the manufacturing of these devices, such that they can be m
more
|
0
|
43082
|
Research/scientific institutio...ns
more
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679785212eaade2e0ee300
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007143
|
GCRF_MRC_AA_MR/S004793/1
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.534172
|
0
|
0
|
0
|
0.534172
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
DRIVERS OF RESISTANCE IN UGAND...A AND MALAWI: THE DRUM CONSORTIUM
more
|
Drivers of Resistance in Ugand...a and Malawi: The DRUM Consortium
more
|
The discovery and development ...of antibiotics is one of the great scientific achievements of the 20th Century, however it rapidly became clear that bacteria quickly become resistant to these lifesaving agents, and the spread of antibiotic-resistant bacteria is now a problem of global concern. The poorest nations on Earth frequently have the greatest burden of severe and life threatening infections, and these nations are likely to suffer most from the spread of untreatable bacteria. There is much that is unknown about how antibiotic resistance spreads globally and this is particularly true of sub-Saharan Africa, where diagnostic laboratories are not commonly available. The 'Drivers of Resistance in Uganda and Malawi' or DRUM Consortium will address how human behaviour and antibacterial usage in the home, around animals and in the wider environment in urban and rural areas of Uganda and Malawi contributes to the spread of antibiotic resistance in bacteria. The consortium is especially interested in the common bacteria E. coli and K. pneumoniae. E. coli is an example of a bacteria that often causes infections in the community, but may also spread around hospitals, whereas K. pneumoniae is a key cause of hospital acquired infections, particularly amongst vulnerable groups such as premature babies. We have chosen to study these bacteria together as they are from the same family and are able to share traits that make them resistant to antibiotics. The DRUM consortium plans to investigate which aspects of behaviour are most important in spreading antibiotic resistance by surveying human behaviour in relation to antibiotics, water, sanitation and hygiene and by investigating bacterial behaviour in response to these stimuli. We plan to use cutting edge mathematical techniques to 'model' which behaviours are most important and then use this information to work with policy experts in Uganda and Malawi to design potential interventions to prevent them from spreading further.
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679785212eaade2e0ee301
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007149
|
GCRF_UKRI_NS_MR/P027873/1
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
2.121939
|
0
|
0
|
0
|
2.121939
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
GCRF PARTNERSHIP FOR INCREASIN...G THE IMPACT OF VECTOR CONTROL (PIIVEC)
more
|
GCRF Partnership for Increasin...g the Impact of Vector Control (PIIVeC)
more
|
UKRI GROW award Partnership fo...r Increasing the Impact of Vector Control (PIIVeC) plans to train scientists in Bukina Faso, Cameroon Malawi and the UK, conduct research and invest in facilities, and bring different disciplines together into advisory groups that can help g
more
|
0
|
12250
|
Infectious disease control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679785212eaade2e0ee302
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007145
|
GCRF_MRC_ZA_MR/T00505X/1
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.819106
|
0
|
0
|
0
|
0.819106
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
A RANDOMISED CONTROLLED TRIAL ...(RCT) TO EVALUATE A SCALABLE ACTIVE CASE FINDING PRIMARY CARE-BASED INTERVENTION FOR TUBERCULOSIS USING A POINT-OF-CARE
more
|
A randomised controlled trial ...(RCT) to evaluate a scalable active case finding primary care-based intervention for tuberculosis using a point-of-care
more
|
TB remains the foremost infect...ious disease killer globally. A starling statistic is that 2 out of every 5 TB cases globally (40%) remain undiagnosed and untreated. These 'missed' or undiagnosed cases are disproportionately concentrated in large peri-urban 'slums' and informal settlements of large cities in Africa and Asia (they are frequently minimally symptomatic but remain infectious). TB will never be brought under control unless this large reservoir of transmission is wiped out. The lack of a sensitive low cost same-day test represented a major challenge to active community-based case finding (ACF) compared to the current model where patients 'self-seek' care (passive case finding). More recently, sensitive TB DNA-detection tests called Gene Xpert (Xpert) have become available. Small portable battery-operated versions of these tests are now available (OMNI). We conducted a large study in South Africa and Zimbabwe (published in 2016) that showed that using the old non-portable version of Xpert on a mini-truck equipped with a generator was feasible and highly effective for ACF. In a subsequent study funded by the American government (XACT II) we showed that using the portable version of Xpert on the back of a small low-cost scalable panel van (in effect a mobile mini clinic) was feasible and had a very high pick-up rate of TB in peri-urban communities (~10% of those undergoing targeted screening, see preliminary data). In the proposed study (XACT III) we will use the same approach, but we need to be sure that such a strategy is scalable and feasible in different settings where the challenges and conditions vary. More importantly, we need to methodologically optimise the ACF model. Thus, we need to determine where Xpert (the diagnostic test) should be optimally placed from a physical location point-of-view, i.e. do we really need to install it on the mobile mini clinic, or, can it be located in centralised laboratories (as it is now) with samples being sent to these laboratories? This is a very important question: we know that sending collected sputum samples to centralised laboratories will be much easier as it uses existing infrastructure, however, the downside is between 20 and 40% of patients fail to come back to collect their results (pre-treatment loss to follow-up, PTLF). Using the diagnostic in the mobile mini van (at point-of-care, POC) dramatically reduces this PTLF enabling quick diagnosis and interrupting transmission. To definitively settle the question we need a study using the 2 different strategies to find out which strategy is most cost-effective yet can rapidly pick up the most cases and minimise transmission. There are 2 other important sub-questions that the study will answer. Chest x-rays, which can identify people at high risk of having TB, can now be automatically read by a computer algorithm (called computer-assisted diagnosis of TB, CAD-TB). It will be very important to know whether mass screening using CAD-TB can tri
more
|
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679786212eaade2e0ee303
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007640
|
GCRF-CICA-R12019-ICA\R1\191238
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.094139
|
0
|
0
|
0
|
0.094139
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
AI-MIRS: AN ONLINE PLATFORM FO...R MALARIA VECTOR SURVEILLANCE IN AFRICA USING ARTIFICIAL INTELLIGENCE AND MOSQUITO INFRARED SPECTROSCOPY
more
|
AI-MIRS: An Online Platform fo...r Malaria Vector Surveillance in Africa using Artificial Intelligence and Mosquito InfraRed Spectroscopy
more
|
Research Grant - Collaboration... between UK and Tanzania. Using infrared and machine learning to estimate the age of mosquitoes, a knowledge gap that currently hinders our ability to predict and measure impact of mosquito control interventions. SDG 3.
more
|
|
12262
|
Malaria control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679786212eaade2e0ee304
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007741
|
UKRI_NS_EP/T024984/1_Clusters
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.044427
|
0
|
0
|
0
|
0.088854
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
50
|
ENABLING OPTIMAL ANTIMICROBIAL... USE IN EAST AFRICA
more
|
Enabling optimal antimicrobial... use in East Africa
more
|
Recently, there has been an in...creasing awareness of the global threat to human and animal health that is presented by the failure of germs, specifically bacteria, to respond to treatment with medicines which formerly killed them, a phenomenon known as Antimicrobial Resistance (AMR). Many approaches are being explored to ameliorate this problem, including the critical need to make better use of antibiotics. Optimal use of antibiotics must ensure both that people unwell with bacterial infections continue to have access to medicines that they need and bacteria do not have the opportunity to develop resistance to these 'magic bullets'. Huge investments have been made in improved laboratory capacity, which permits us to detect and describe AMR and report this problem through surveillance networks to governments and international agencies. These investments in laboratory surveillance have not been matched by enhanced surveillance of or interventions to improve antibiotic use (ABU), particularly in low income countries. We propose to bring together four Global Challenges Research Fund (GCRF) investments in the field of AMR in East Africa into a GCRF cluster. We will collectively take responsibility for reviewing and 'synthesising' all of our ABU research findings from the East African context from across human and animal health. We will work together to co-design 'an essential information package' to optimise ABU in the East African context and to define an intervention using this package to change ABU behaviours in communities and health systems.
more
|
|
43082
|
Research/scientific institutio...ns
more
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679786212eaade2e0ee305
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007135
|
GCRF_MRC_BFA_MR/P006876/1
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.086988
|
0
|
0
|
0
|
0.086988
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
A COMPARATIVE TRIAL OF SEASONA...L VACCINATION WITH THE MALARIA VACCINE RTS,S/AS01, SEASONAL MALARIA CHEMOPREVENTION AND THE TWO INTERVENTIONS COMBINED
more
|
A comparative trial of seasona...l vaccination with the malaria vaccine RTS,S/AS01, seasonal malaria chemoprevention and the two interventions combined
more
|
There has been substantial pro...gress in the control of malaria during the past decade, but it is estimated that in 2015 there were still 438 000 deaths from malaria, despite widespread deployment of insecticide treated bednets and an increase in access to diagnosis and effective treatment: new tools and approaches are needed. In the African Sahel and sub-Sahel, the risk of malaria is concentrated in the few months of the rainy season, although some transmission continues during the rest of the year. The seasonality of malaria in this part of Africa has allowed the development of a control measure called seasonal malaria chemoprevention (SMC), which involves treatment of young children, regardless of whether they have any symptoms, with the antimalarials sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) at monthly intervals on four occasions during the malaria transmission season, a regimen which is very demanding on health care givers and recipient children. The malaria vaccine RTS,S/AS01 has been in development for over 20 years. A recent trial conducted in 15,439 children showed that when three doses of the vaccine were given to children aged 5-17 months, followed by a fourth dose a year later, the vaccine provided 37% protection against clinical attacks of malaria over a period of 4 years, and a similar level of protection against severe malaria. The vaccine caused febrile convulsions in about 1% of children and there was a small, unexplained, increase in the incidence of meningitis in vaccine recipients. These findings were reviewed by the European Medicine Agency in July 2015 and, based on the balance of benefits and risks, the Agency gave the vaccine a positive opinion. WHO has subsequently recommended that several large pilot implementation studies should be done before the vaccine is deployed more widely and that alternative approaches to its delivery should be explored. A characteristic feature of the vaccine is that it produces high levels of protection in the first few months after vaccination but that this subsequently wanes. Vaccine efficacy of 86% (26/30 subjects protected) was obtained in a recent trial in USA military volunteers challenged shortly after three doses of vaccine had been given, the last dose at a lower concentration than usual. The aim of this study is to take advantage of the high initial efficacy of RTS,S/AS01 to investigate its potential to provide protection to children exposed to malaria for just a few months each year. A three arm trial is proposed which will compare (a) administration of three doses of RTS,S/AS01 to young children followed by a fourth and a fifth dose at the beginning of two subsequent malaria transmission season (b) administration of SMC with SP + AQ as recommended by WHO (c) the combination of these two interventions. The main objectives of the trial will be to determine whether RTS,S/AS01 provides a similar level of protection to that of SMC and is equally cost effective a
more
|
Malaria
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679786212eaade2e0ee306
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007133
|
GCRF_MRC_BWA_MR/P011357/1
|
3
|
South of Sahara, regional
|
South of Sahara
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.086229
|
0
|
0
|
0
|
0.086229
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SUB-SAHARAN AFRICAN NETWORK FO...R CONGENITAL ANOMALIES: SURVEILLANCE, PREVENTION AND CARE
more
|
Sub-Saharan African Network fo...r Congenital Anomalies: Surveillance, Prevention and Care
more
|
In Sub-Saharan Africa, there h...as been limited attention to congenital anomalies (spina bifida, cleft palate, limb defects, Down Syndrome and many others) which has led to a large gap in knowledge and understanding about their frequency and causes, how best to prevent them happening through public health programs, or how to meet the specialist healthcare and social needs of affected children and families in order to improve survival and quality of life. Currently, congenital anomalies are estimated to account for approximately 10% of child deaths under 5 years of age. There is a new urgency to tackle this problem. The Sustainable Development Goals set out targets for reducing neonatal and childhood mortality and morbidity, for reducing health inequity where vulnerable populations (such as those with congenital anomalies) are left behind, and to make sure that all children have access to quality healthcare. In addition, two recent events have shown the need to have better information about congenital anomalies in the population. Africa has the highest HIV burden in the world, and it is important that pregnant women receive the best antiviral medication for themselves and their babies, but a concern has been raised that one of the new antiretrovirals may raise the risk of congenital anomaly - much more data and research is needed to address this and related questions urgently. Recently in Latin America, the Zika virus epidemic focused the world's attention on the potential for maternal infections to cause congenital anomalies, and this again highlights the lack of knowledge about the effect of maternal infections in Africa, and lack of preparedness for new epidemics. This one year seed project will set up a Sub-Saharan African Network for Congenital Anomalies: Surveillance, Prevention and Care. The aim of the network is to promote the prevention of Congenital Anomalies, and care for affected children and families, by building an evidence base through surveillance and research, improving capacity for collaborative research, and paving a pathway to improve policy and practice. We have gathered together multiple stakeholders (academic researchers, ministry of health, patient organisations, healthcare professionals) from 9 African countries, including all those with the most experience in this area along with key international partners. By the end of one year, we will have agreed a governance structure, data sharing mechanism, 'community of practice' website, and research priorities and further funding proposals. We will also have agreed a position paper setting out the burden of congenital anomalies at the individual, family and community level based on available data, modelling and estimation, and survey of policy and practice and experience in Sub-Saharan Africa. This position paper will be the basis for making the case with national ministries of health to raise the priority of congenital anomalies in their national health agendas. We will also s
more
|
TB
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679786212eaade2e0ee307
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020006711
|
GCRF_BBSRC_NS_BB/L018926/1
|
3
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0
|
0.000246
|
0
|
0
|
0
|
0.000246
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SOCIAL, ECONOMIC AND ENVIRONME...NTAL DRIVERS OF ZOONOSES IN TANZANIA (SEEDZ)
more
|
Social, Economic and Environme...ntal Drivers of Zoonoses in Tanzania (SEEDZ)
more
|
Research Grant – interdiscip...linary research looking into the drivers, risks and impacts of livestock zoonotic diseases in Tanzania. Will result in improved clinical awareness and diagnostic capacity, benefitting the livestock communities, as well as scien
more
|
0
|
31182
|
Agricultural research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679787212eaade2e0ee308
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007154
|
GCRF_MRC_TZA_MR/S004815/1
|
3
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.661894
|
0
|
0
|
0
|
0.661894
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
SUPPORTING THE NATIONAL ACTION... PLAN FOR ANTIMICROBIAL RESISTANCE (SNAP-AMR) IN TANZANIA
more
|
Supporting the National Action... Plan for Antimicrobial Resistance (SNAP-AMR) in Tanzania
more
|
Antimicrobial resistance (AMR)..., the ability of bacteria to resist the effect of drugs, is a threat to human and animal health in resource rich nations like the UK and low and middle income countries like the United Republic of Tanzania. In Tanzania, as in many low and middle income countries, the AMR problem is compounded by the fact that people and livestock often live close together and widespread use of antimicrobials in both. In response to a global call to action from the World Health Organisation, Tanzania has created an ambitious National Action Plan to combat AMR, including improving awareness and understanding of the AMR problem among policy makers, professionals and the public and enhancing surveillance, research, infection prevention and antimicrobial stewardship in people and livestock. Successful implementation of the NAP is challenged by lack of human and financial resources, making prioritisation of activities and interventions an essential component of an effective and efficient campaign to control AMR. Our research will provide new evidence to support this prioritisation and targeting, taking an approach that recognises that individuals are part of a larger system and that behaviour of professionals and the public may depend on policy, regulations or knowledge, but also on cultural background, social norms and access to medical, veterinary or diagnostic infrastructure and drugs. Our team of UK and Tanzania-based researchers and policy experts will take an interdisciplinary approach, working with a wide range of biological and social scientists as well as health professionals and community members, to provide novel insights into cultural, socio-economic and biological drivers of antimicrobial use (AMU) in hospitals and the community and in contextually appropriate methods of communication around those issues. The origin of AMR problems can be described as hospital-, community- or livestock-associated so we will work with doctors and nurses, householders and patients, and veterinarians and livestock keepers as well as (in)formal drug providers and other stakeholders to investigate knowledges, beliefs, attitudes and practices around health and AMU/AMR. We will compare health care settings (health centres, district, regional and referral hospitals) and livestock keeping communities (Chagga, Masaai and Sukuma) to reflect a range of professional and cultural contexts. Using focus group discussions, questionnaires and interviews, we will examine factors that influence prescribing and use of antimicrobials and through choice experiments we will examine how changes in e.g. knowledges, social norms or access might change such behaviour. To complement the socio-economic investigations, we will use DNA-sequencing of hospital -, community - or livestock-associate bacteria in combination with mathematical modelling approaches to establish the relative contribution of different sources and transmission routes to the clinical and economic burd
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679787212eaade2e0ee309
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008511
|
MRC_TZA_MR/P020593/1
|
3
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.16413
|
0
|
0
|
0
|
0.16413
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
IMMUNE RESPONSES IN MALARIA-EX...POSED CHILDREN IMMUNISED WITH A NEW GENERATION BLOOD-STAGE MALARIA VACCINE.
more
|
Immune responses in malaria-ex...posed children immunised with a new generation blood-stage malaria vaccine.
more
|
MRC African Res Leaders Sep 20...16 award - Immune responses in malariaexposed children immunised with a new generation bloodstage malaria vaccine.
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679787212eaade2e0ee30a
|
2020
|
Germany
|
Foreign Office
|
2020008514
|
6612778
|
3
|
Syrian Arab Republic
|
Middle East
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
5.895157
|
0
|
0
|
0
|
5.895157
|
|
0
|
|
0
|
Emergency projects (meeting ad...ditional funding needs)
more
|
|
100
|
EMERGENCY MEDICAL ASSISTANCE I...N SYRIA
more
|
Emergency medical assistance i...n Syria
more
|
Emergency medical assistance f...or conflict-affected internally displaced persons and residents in the Turkish-Syrian border area
more
|
0
|
72010
|
Material relief assistance and... services
more
|
|
VIII.1. Emergency Response
|
22000
|
Donor country-based NGO
|
Donor country-based NGO
|
|
|
|
65679787212eaade2e0ee30b
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008509
|
MRC_TZA_MR/S012796/1
|
3
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.097755
|
0
|
0
|
0
|
0.097755
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
POLICY ANALYSIS OF THE DRIVERS... OF ANTIMICROBIAL RESISTANCE WITHIN TANZANIA'S ONE-HEALTH CARE SYSTEMS
more
|
Policy analysis of the drivers... of antimicrobial resistance within Tanzania's one-health care systems
more
|
MRC/HSRI award aims to uncover... the covert and overt drivers of AMR within Tanzania's public health and animal health system using a combination of qualitative methods and an interdisciplinary 'One Health' research approach
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679787212eaade2e0ee30c
|
2020
|
Switzerland
|
Swiss Agency for Development a...nd Co-operation
more
|
2020008513
|
7F-01349.11.19
|
3
|
Mozambique
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.023962
|
0
|
0
|
|
0.023962
|
|
|
|
|
COVID-19
|
COVID-19 Personal Protective E...quipment
more
|
100
|
ETHANOL PRODUCTION_COVID 19 - ...SMALL ACTION CREDIT
more
|
Ethanol Production_Covid 19 - ...small action credit
more
|
Les crédits globaux pour peti...tes actions permettent le financement d'opérations ponctuelles, peu coûteuses, significatives en termes de développement, à composantes diverses (techniques, sociales, organisationnelles et de gestion, politique, économique, informative, etc.)
more
|
|
31120
|
Agricultural development
|
3.3,2.a
|
III.1.a. Agriculture
|
22000
|
Donor country-based NGO
|
HELVETAS Swiss Intercooperatio...n
more
|
|
COVID-19
|
|
65679787212eaade2e0ee30d
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007155
|
GCRF_MRC_THA_MR/S004394/1
|
3
|
Thailand
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.463245
|
0
|
0
|
0
|
0.463245
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ADJUNCT ANTIBODY THERAPY FOR S...EVERE ANTIBIOTIC-RESISTANT ACINETOBACTER BAUMANNII INFECTIONS
more
|
Adjunct antibody therapy for s...evere antibiotic-resistant Acinetobacter baumannii infections
more
|
Unlike in the UK and other Wes...tern countries, the bacteria Acinetobacter baumannii is a common cause of pneumonia and other infections in Asian countries. Unfortunately A. baumannii both often causes severe infections and is frequently highly resistant to antibiotics, including penems and extended spectrum penicillins, and A. baumannii infections therefore have a high mortality and require considerable hospital resources. We will investigate whether antibodies that bind to the surface of A. baumannii bacteria could be used as way of providing additional treatment to patients with an A. baumannii infection along with antibiotics. We will look for several protein targets for an antibody therapy that can increase killing of A. baumannii by human white cells or which by inhibiting mechanisms of antibiotic resistance makes a previously ineffective antibiotic able to kill A. baumannii. To do so we will: Aims 1 and 2. Use information that we have recently obtained on the gene content of 300 Thai A. baumannii strains to identify proteins present in most strains, and use these to construct what is called an antigenome array. Antigenome arrays allow all the proteins that cause an antibody response to be identified, and we will use the A. baumannii conserved protein antigenome array to identify which proteins can cause an antibody response after human or mouse A. baumannii infections. Aims 3. Identify which A. baumannii proteins are abundant on the bacteria during infection or in response to antibiotics using a technology called RNAseq to see which genes are highly expressed during infection or when the bacteria has been stressed by antibiotics, these genes should b particularly good candidates for an antibody therapy. Aim 4. Use the data obtained in aims 1 to 3 to identify which A. baumannii proteins should be investigated further as potential targets for an antibody therapy. We will make each protein antigen and obtain rabbit antibodies to the protein to test the ability of the antibody to recognise and kill different A. baumannii strains using laboratory assays of immune function and mouse models of infection. From these data we select a few protein antigens for use in a protective multivalent antibody therapy that targets several important proteins rather than just individual protein antigens as targeting several proteins should make the treatment more effective as a therapy. Aim 5. To identify which patients with A. baumannii infection and when during infection those patients could benefit from an antibody therapy we will collect data on 100 Thai patients with proven A. baumannii infection. In addition we will purify antibodies developing in these patients as a result of the A. baumannii infection for use in our blood infection model to confirm that antibody therapy can inhibit A. baumannni growth in the blood or resistance to antibiotics. Overall the project will identify which A. baumannii proteins would make good targets for an antibody thera
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679788212eaade2e0ee30e
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007156
|
GCRF_MRC_THA_MR/S004769/1
|
3
|
Thailand
|
Far East Asia
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.648018
|
0
|
0
|
0
|
0.648018
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
ONE HEALTH DRIVERS OF ANTIBACT...ERIAL RESISTANCE IN THAILAND
more
|
One Health Drivers of Antibact...erial Resistance in Thailand
more
|
Antibacterial Resistance (ABR)... is a significant source of excess mortality in Overseas Development Assistance (ODA) countries and constitutes a major, increasing threat to wellbeing and economic development. Antimicrobial Resistance (AMR), predominantly ABR, is estimated to have caused 38,000 deaths and an economic loss of 1.2 billion US$ in Thailand in 2010. Because of good record keeping and surveillance, Thailand has been used as an exemplar for characteristics of ABR in ODA countries. ABR is common in human, environmental and animal bacterial isolates. However, ABR has mostly been studied separately in discrete sectors (e.g. hospital patients or poultry). The key drivers of ABR relevant to human health cannot be pinpointed in this way because the selection and transmission of ABR results from interactions between humans, animals, and the environment. A 'One Health' approach to the problem is required. During this consortium project, we will study the Enterobacteriaceae family bacteria Klebsiella pneumoniae (Kp) and Escherichia coli (Ec), which reside in the human and animal gut, are common in environments contaminated with faeces, are are considered a significant threat to human health in Thailand. They are commonly carbapenem- and/or 3rd-generation cephalosporin-resistant (3GCR), which are drugs commonly used for serious infections. Carbapenem-resistant Enterobacteriaceae (CRE) are also recognised by WHO as one of the highest priority pathogens globally for which new ABs are urgently needed. Ec and Kp cause a range of infections in hospitalized patients (e.g. surgical site, intra-abdominal, pneumonia, sepsis) and serious community-acquired infections (e.g. complicated urinary tract infection, pyogenic liver abscess, meningitis). The prevalence of 3GCR Kp and Ec in human infections in Thailand has been increasing from less than 10% in 1999 to 50% in 2016, and of carbapenem-resistant Kp from none prior to 2010 to 10%-20% in 2016. Our consortium's vision is to build a holistic picture of the drivers of ABR in Thailand and to use this information to benefit the Thai people, and as an exemplar for other ODA countries. The term 'driver' may refer to: 1) a material condition or substance, such as a chemical (e.g. an Antibiotic), which, at a particular concentration, selects for the increased prevalence of ABR bacteria, 2) an action, such as exposing bacteria to that chemical by taking an antibiotic, or 3) a socioeconomic condition or circumstance which accounts for that action (e.g. the economic necessity to keep working in the face of illness). A full understanding of ABR drivers at every level is important for the design of effective and appropriate interventions to limit ABR. Hence, this interdisciplinary consortium will investigate them all. Our study area will be the Mae Klong-Ta Chin Basin, which covers an area of 80x80 km in the central and western part of Thailand. This is the area where the Mae Klong and Ta Chin rivers run from their m
more
|
0
|
12182
|
Medical research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679788212eaade2e0ee30f
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008526
|
MRC_ZMB_MR/S004998/1
|
3
|
Zambia
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.202206
|
0
|
0
|
0
|
0.202206
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EFFECTS OF METRONIDAZOLE PLUS ...INTERMITTENT PREVENTIVE TREATMENT OF MALARIA IN PREGNANCY ON BIRTH OUTCOMES: A RANDOMISED CONTROLLED TRIAL IN ZAMBIA
more
|
Effects of metronidazole plus ...intermittent preventive treatment of malaria in pregnancy on birth outcomes: a randomised controlled trial in Zambia
more
|
JGHT 8 Full 2018 award - Effe...cts of metronidazole plus intermittent preventive treatment of malaria in pregnancy on birth outcomes: a randomised controlled trial in Zambia
more
|
0
|
12182
|
Medical research
|
|
|
11000
|
Donor Government
|
Donor Government
|
|
|
|
65679788212eaade2e0ee310
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020007654
|
GCRF-CICA-ICAR12020-ICAR120139...9
more
|
3
|
Zimbabwe
|
South of Sahara
|
Other LICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.096191
|
0
|
0
|
0
|
0.096191
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PAEDIATRIC SCHISTOSOMIASIS: IN...VESTIGATING THE IMPACT AND MECHANISM OF A NOVEL STRATEGY TO OPTIMISE THE BENEFITS OF ANTIHELMINTHIC TREATMENT
more
|
Paediatric schistosomiasis: in...vestigating the impact and mechanism of a novel strategy to optimise the benefits of antihelminthic treatment
more
|
Research Grant - Collaboration... between UK and Zimbabwe. Evaluating a strategy for including preschool children in national schistosome control programs that addresses the safety and operational challenges, while providing optimal health outcomes for the children. Schistosomiasis is a parasitic disease affecting 120 million people on the African continent, predominantly children. SDGs 1,3.
more
|
NTD - Schisto
|
12250
|
Infectious disease control
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679788212eaade2e0ee311
|
2020
|
United Kingdom
|
Department for Business, Innov...ation and Skills
more
|
2020008294
|
BBSRC_AA_BB/P005888/1
|
3
|
Zimbabwe
|
South of Sahara
|
Other LICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.060447
|
0
|
0
|
0
|
0.060447
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
EPIDEMIOLOGICAL CONSEQUENCES O...F REPRODUCTIVE SENESCENCE IN A LONG-LIVED VECTOR
more
|
Epidemiological consequences o...f reproductive senescence in a long-lived vector
more
|
This project will develop epid...emiological and demographic models essential for predicting and mitigating risks of vectorborne diseases to livestock and humans, including animal African trypanosomiasis (AAT), which is transmitted by tsetse flies across subSaharan Africa.
more
|
NTDs
|
31182
|
Agricultural research
|
|
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
65679789212eaade2e0ee312
|
2014
|
United States
|
AID
|
2014011396
|
76_42884
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.10388
|
0
|
0
|
0
|
0.10388
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - MALARIA
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Malaria
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
65679789212eaade2e0ee313
|
2014
|
United States
|
AID
|
2014011400
|
76_42884
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.2436
|
0
|
0
|
0
|
0.2436
|
0
|
0
|
0.2436
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - PANDEMIC INFLUENZA AND OTHER EMERGING THREATS (PIOET)
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Pandemic Influenza and Other Emerging Threats (PIOET)
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
65679789212eaade2e0ee314
|
2014
|
United States
|
AID
|
2014011403
|
76_42884
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.44914
|
0
|
0.2
|
0
|
0.44914
|
0
|
0.2
|
0.44914
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - TUBERCULOSIS
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Tuberculosis
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12263
|
Tuberculosis control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
65679789212eaade2e0ee315
|
2014
|
United States
|
AID
|
2014029937
|
76_46547
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
2.36423
|
1.28819
|
0
|
0
|
2.36423
|
1.28819
|
0
|
0
|
0
|
2.36423
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Donor Government
|
|
|
|
65679789212eaade2e0ee316
|
2014
|
United States
|
AID
|
2014011408
|
76_42884
|
1
|
Indonesia
|
Far East Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0
|
0.13113
|
0
|
0
|
0
|
0.13113
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - PANDEMIC INFLUENZA AND OTHER EMERGING THREATS (PIOET)
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Pandemic Influenza and Other Emerging Threats (PIOET)
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
65679789212eaade2e0ee317
|
2014
|
United States
|
AID
|
2014011409
|
76_42884
|
1
|
Indonesia
|
Far East Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.3
|
0.30267
|
0
|
0
|
0.3
|
0.30267
|
0
|
0.3
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - TUBERCULOSIS
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Tuberculosis
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12263
|
Tuberculosis control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
6567978a212eaade2e0ee318
|
2014
|
United States
|
AID
|
2014029936
|
76_46547
|
1
|
Kenya
|
South of Sahara
|
Other LICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.45
|
0
|
0.0244
|
0
|
0.45
|
0
|
0.0244
|
0
|
0
|
0.45
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Donor Government
|
|
|
|
6567978a212eaade2e0ee319
|
2014
|
United States
|
AID
|
2014029583
|
76_46199
|
3
|
Nigeria
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.3
|
0
|
0
|
0
|
0.3
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
HEALTH RESEARCH CHALLENGE FOR ...IMPACT - MALARIA
more
|
Health Research challenge for ...Impact - Malaria
more
|
The aim of Health Research Cha...llenge for Impact (HRCI) is to accelerate the development and introduction of new, feasible, culturally acceptable, low-cost, preventive and curative interventions for the main causes of maternal, newborn and child deaths.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
University, college or other t...eaching institution, research institute or think?tank
more
|
|
|
|
6567978a212eaade2e0ee31a
|
2014
|
United States
|
AID
|
2014029935
|
76_46547
|
1
|
Nigeria
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.4
|
0
|
0
|
0
|
0.4
|
0
|
0
|
0
|
0
|
0.4
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Donor Government
|
|
|
|
6567978a212eaade2e0ee31b
|
2014
|
United States
|
AID
|
2014011411
|
76_42884
|
1
|
Philippines
|
Far East Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.5
|
0
|
0
|
0
|
0.5
|
0
|
0
|
0.5
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - TUBERCULOSIS
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Tuberculosis
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12263
|
Tuberculosis control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
6567978a212eaade2e0ee31c
|
2014
|
United States
|
AID
|
2014029934
|
76_46547
|
1
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.4
|
0
|
0
|
0
|
0.4
|
0
|
0
|
0
|
0
|
0.4
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11000
|
Donor government
|
Donor Government
|
|
|
|
6567978a212eaade2e0ee31d
|
2015
|
United States
|
AID
|
2015009595eus
|
76_39459
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
1.98411
|
0.526581
|
0
|
0
|
1.98411
|
0.526581
|
0
|
0
|
0
|
1.98411
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11001
|
Central Government
|
Central Government
|
|
|
|
6567978a212eaade2e0ee31e
|
2015
|
United States
|
AID
|
2015010975
|
76_42974
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.3
|
0
|
0
|
0
|
0.3
|
0
|
0
|
0.3
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - MALARIA
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Malaria
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
6567978b212eaade2e0ee31f
|
2015
|
Germany
|
BMBF
|
2015010981
|
01DN14003
|
3
|
Chile
|
South America
|
UMICs
|
ODA Grants
|
1
|
10
|
110
|
D02
|
0
|
0.00332108
|
0
|
0
|
0
|
0.00332108
|
0
|
0
|
|
0
|
Other health problems
|
Other health problems Research... and Development
more
|
100
|
FUNDING FOR SCIENTIST EXCHANGE...S, GRANTS
more
|
Funding for scientist exchange...s, grants
more
|
Workshop - Occupational diseas...es taking particular account of symptoms in mine workers and the use of biotechnological methods to combat diseases - Capacity building in the field of education and research
more
|
|
12181
|
Medical education/training
|
|
I.2.a. Health, General
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Higher education institution
|
|
|
|
6567978b212eaade2e0ee320
|
2015
|
United States
|
AID
|
2015010984ybl
|
76_42974
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.2
|
0
|
0
|
0
|
0.2
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - TUBERCULOSIS
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Tuberculosis
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12263
|
Tuberculosis control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
6567978b212eaade2e0ee321
|
2015
|
United States
|
AID
|
2015009595
|
76_39459
|
3
|
Kenya
|
South of Sahara
|
Other LICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.45
|
0
|
0
|
0
|
0.45
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11001
|
Central Government
|
Central Government
|
|
|
|
6567978b212eaade2e0ee322
|
2015
|
United States
|
AID
|
2015009595wnb
|
76_39459
|
1
|
Nigeria
|
South of Sahara
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.427
|
0.213212
|
0
|
0
|
0.427
|
0.213212
|
0
|
0
|
0
|
0.427
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11001
|
Central Government
|
Central Government
|
|
|
|
6567978b212eaade2e0ee323
|
2015
|
United States
|
AID
|
2015010984bzn
|
76_42974
|
3
|
Philippines
|
Far East Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.102788
|
0
|
0
|
0
|
0.102788
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - TUBERCULOSIS
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Tuberculosis
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12263
|
Tuberculosis control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
6567978b212eaade2e0ee324
|
2015
|
United States
|
AID
|
2015009595twf
|
76_39459
|
3
|
Tanzania
|
South of Sahara
|
LDCs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.150537
|
0
|
0
|
0
|
0.150537
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11001
|
Central Government
|
Central Government
|
|
|
|
6567978c212eaade2e0ee325
|
2016
|
United States
|
Department of Health and Human... Services
more
|
2016003065B
|
34_9097
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.681665
|
0
|
0
|
0
|
0.681665
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CDC: PROTECTING AND IMPROVING ...HEALTH GLOBALLY: STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENT
more
|
CDC: Protecting and Improving ...Health Globally: Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevent
more
|
Institutional Research Collabo...ration between the Liverpool School of Tropical Medicine and the U.S. Department of Health and Human Services - Centers for Disease Control and Prevention
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Liverpool School of Tropical M...edicine
more
|
|
|
|
6567978c212eaade2e0ee326
|
2016
|
United States
|
Department of Health and Human... Services
more
|
2016003065A
|
34_9097
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.155706
|
0
|
0
|
0
|
0.155706
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CDC: PROTECTING AND IMPROVING ...HEALTH GLOBALLY: STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENT
more
|
CDC: Protecting and Improving ...Health Globally: Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevent
more
|
Institutional Research Collabo...ration between the Liverpool School of Tropical Medicine and the U.S. Department of Health and Human Services - Centers for Disease Control and Prevention
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Liverpool School of Tropical M...edicine
more
|
|
|
|
6567978c212eaade2e0ee327
|
2016
|
United States
|
Department of Health and Human... Services
more
|
2016003066B
|
34_9098
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.244163
|
0
|
0
|
0
|
0.244163
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CDC: PROTECTING AND IMPROVING ...HEALTH GLOBALLY: STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENT
more
|
CDC: Protecting and Improving ...Health Globally: Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevent
more
|
Institutional Research Collabo...ration between the Liverpool School of Tropical Medicine and the U.S. Department of Health and Human Services - Centers for Disease Control and Prevention
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Liverpool School of Tropical M...edicine
more
|
|
|
|
6567978c212eaade2e0ee328
|
2016
|
United States
|
Department of Health and Human... Services
more
|
2016003066A
|
34_9098
|
3
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.221128
|
0
|
0
|
0
|
0.221128
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CDC: PROTECTING AND IMPROVING ...HEALTH GLOBALLY: STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENT
more
|
CDC: Protecting and Improving ...Health Globally: Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevent
more
|
Institutional Research Collabo...ration between the Liverpool School of Tropical Medicine and the U.S. Department of Health and Human Services - Centers for Disease Control and Prevention
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Liverpool School of Tropical M...edicine
more
|
|
|
|
6567978c212eaade2e0ee329
|
2016
|
United States
|
Department of Health and Human... Services
more
|
2016003068B
|
34_9099
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
3.21681
|
0.118844
|
0
|
0
|
3.21681
|
0.118844
|
0
|
0
|
0
|
3.21681
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CDC: PROTECTING AND IMPROVING ...HEALTH GLOBALLY: STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENT
more
|
CDC: Protecting and Improving ...Health Globally: Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevent
more
|
Institutional Research Collabo...ration between the Liverpool School of Tropical Medicine and the U.S. Department of Health and Human Services - Centers for Disease Control and Prevention
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Liverpool School of Tropical M...edicine
more
|
|
|
|
6567978c212eaade2e0ee32a
|
2016
|
United States
|
Department of Health and Human... Services
more
|
2016003068A
|
34_9099
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.7406
|
0.026108
|
0
|
0
|
0.7406
|
0.026108
|
0
|
0
|
0
|
0.7406
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CDC: PROTECTING AND IMPROVING ...HEALTH GLOBALLY: STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENT
more
|
CDC: Protecting and Improving ...Health Globally: Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevent
more
|
Institutional Research Collabo...ration between the Liverpool School of Tropical Medicine and the U.S. Department of Health and Human Services - Centers for Disease Control and Prevention
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
51000
|
University, college or other t...eaching institution, research institute or think-tank
more
|
Liverpool School of Tropical M...edicine
more
|
|
|
|
6567978c212eaade2e0ee32b
|
2016
|
United States
|
Agency for International Devel...opment
more
|
2016017925
|
76_40499
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
2.45318
|
2.15446
|
0
|
0
|
2.45318
|
2.15446
|
0
|
0
|
0
|
2.45318
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
MALARIA VACCINE DEVELOPMENT PR...OGRAM (MVDP) - MALARIA
more
|
Malaria Vaccine Development Pr...ogram (MVDP) - Malaria
more
|
MVDP, is committed to undertak...e, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.
more
|
|
12262
|
Malaria control
|
|
I.2.b. Basic Health
|
11001
|
Central Government
|
Central Government
|
|
|
|
6567978d212eaade2e0ee32c
|
2016
|
United States
|
Agency for International Devel...opment
more
|
2016020320
|
76_44188
|
1
|
Developing countries, unspecif...ied
more
|
Regional and Unspecified
|
Part I unallocated by income
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0.7
|
0
|
0.078257
|
0
|
0.7
|
0
|
0.078257
|
0.7
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
PARTNERSHIPS FOR ENHANCED ENGA...GEMENT IN RESEARCH (PEER) PROGRAM - TUBERCULOSIS
more
|
Partnerships for Enhanced Enga...gement in Research (PEER) program - Tuberculosis
more
|
The Partnerships for Enhanced ...Engagement in Research (PEER) program is administered by the U.S. National Academy of Sciences (NAS). PEER is a competitive grants program that invites scientists in developing countries, partnered with USG-supported collaborators, to apply for funds to support research and capacity-building activities on topics with strong potential development impacts. This innovative program is designed to leverage the investments other USG-supported agencies have made in scientific research and training while supporting the initiatives of developing country scientists.
more
|
|
12263
|
Tuberculosis control
|
|
I.2.b. Basic Health
|
22000
|
National NGOs
|
National Academy of Sciences
|
|
|
|
6567978d212eaade2e0ee32d
|
2016
|
United States
|
Department of Health and Human... Services
more
|
2016003070A
|
34_9101
|
3
|
Georgia
|
South & Central Asia
|
LMICs
|
ODA Grants
|
1
|
10
|
110
|
C01
|
0
|
0.239014
|
0
|
0
|
0
|
0.239014
|
0
|
0
|
0
|
0
|
Communicable diseases
|
Communicable diseases Research... and Development
more
|
100
|
CDC: PROTECTING AND IMPROVING ...HEALTH GLOBALLY: STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENT
more
|
CDC: Protecting and Improving ...Health Globally: Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevent
more
|
Strengthening Public Health th...rough Surveillance, Epidemiologic Research Capacity in Georgia
more
|
|
12250
|
Infectious disease control
|
|
I.2.b. Basic Health
|
12001
|
Central Government
|
Central Government
|
|
|
